Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | RHEB | Q15382 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13312969 | 0.87 | GSK3B (0.49) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2950875 | 0.86 | GSK3B (0.48) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL13312968 | 0.85 | GSK3B (0.46) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2641186 | 0.84 | GSK3B (0.66) | GSK3BALDH1A1KDM4ECYP3A4HPGD | |
| SCHEMBL2950001 | 0.83 | NPC1 (0.53) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2943223 | 0.83 | RHEB (0.51) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2951044 | 0.83 | PKN1 (0.53) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2950072 | 0.83 | GSK3B (0.46) | GSK3BALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL2945316 | 0.82 | GSK3B (0.43) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 | |
| SCHEMBL2638896 | 0.82 | RHEB (0.63) | GSK3BALDH1A1KDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4792455-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | claimed |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2009-02-12 | — | — | US | claimed |
| EP-1725543-B1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | EP | claimed |
| US-20070173503-A1 | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | claimed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | claimed |
| EP-1725543-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | claimed |
| EP-1723137-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | Aventis Pharma S.A. (FR) | 2006-11-22 | — | — | EP | claimed |
| WO-2005085231-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2005-09-15 | — | — | WO | claimed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | claimed |
| US-7754713-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| US-7754713-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| US-7754713-B2 | 4-benzimidazol-2-ylpyridazin-3-one derivatives | AVENTIS PHARMA S.A. (FR) | 2010-07-13 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| EP-1725543-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| EP-1723137-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | Aventis Pharma S.A. (FR) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005085231-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173503-A1 | Novel 4-benzimidazol-2-ylpyridazin-3-one derivatives | CDK2, CDK1, CDK4 | GSK3B 724/4885ALDH1A1 1700/4885KDM4E 822/4885 |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | GSK3B, GSK3A, PYGB | GSK3B 1/4885ALDH1A1 1912/4885KDM4E 1162/4885 |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | CDK2, CDK1, CDK4 | GSK3B 757/4885ALDH1A1 1627/4885KDM4E 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.